Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of simlukafusp alfa (RO6874281) with or without atezolizumab in advanced solid tumors
jRCT2080224653Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of simlukafusp alfa in Nonhematologic neoplasms (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of simlukafusp alfa monotherapy and combination with atezolizumab. Started Apr 2019; status: completed.
02
Drugs
simlukafusp alfa
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224653.